Serum Syndecan-1: A Novel Biomarker for Pancreatic Ductal Adenocarcinoma

Doron Yablecovitch, Shomron Ben-Horin, Orit Picard, Miri Yavzori, Ella Fudim, Moshe Nadler, Idan Levy, Emad Sakhnini, Alon Lang, Tal Engel, Maor Lahav, Talia Saker, Sandra Neuman, Limor Selinger, Revital Dvir, Maria Raitses-Gurevich, Talia Golan, Ido Laish

Research output: Contribution to journalArticlepeer-review


INTRODUCTION: Syndecan-1 (SDC1) has multiple functions in tumorigenesis in general and specifically in pancreatic cancer. We aimed to evaluate SDC1 as a diagnostic and prognostic biomarker in patients with pancreatic ductal adenocarcinoma (PDAC). METHODS: In this case-control study, patients newly diagnosed with a biopsy-proven PDAC were enrolled alongside healthy individuals in a derivation-validation cohort design. Serum SDC1 was measured by enzyme-linked immunoassay. The diagnostic accuracy of SDC1 levels for diagnosing PDAC was computed. A unified cohort enriched with additional early-stage patients with PDAC was used to evaluate the association of SDC1 with survival outcomes and patient characteristics. RESULTS: In the derivation cohort, serum SDC1 levels were significantly higher in patients with PDAC (n 5 39) compared with healthy controls (n 5 20) (40.1 ng/mL, interquartile range 29.8–95.3 vs 25.6 ng/mL, interquartile range 17.1–29.8, respectively; P < 0.001). The receiver operating characteristic analysis area under the curve was 0.847 (95% confidence interval 0.747–0.947, P < 0.001). These results were replicated in a separate age-matched validation cohort (n 5 38 PDAC, n 5 38 controls; area under the curve 0.844, 95% confidence interval 0.757–0.932, P < 0.001). In the combined-enriched PDAC cohort (n 5 110), using a cutoff of 35 ng/mL, the median overall 5-year survival between patients below and above this cutoff was not significantly different, although a trend for better survival after 1 year was found in the lower level group (P 5 0.06). There were 12 of the 110 patients with PDAC (11%) who had normal CA 19-9 in the presence of elevated SDC1. DISCUSSION: These findings suggest serum SDC1 as a promising novel biomarker for early blood-based diagnosis of pancreatic cancer.

Original languageEnglish
Article numbere00473
JournalClinical and Translational Gastroenterology
Issue number5
StatePublished - 1 May 2022


Dive into the research topics of 'Serum Syndecan-1: A Novel Biomarker for Pancreatic Ductal Adenocarcinoma'. Together they form a unique fingerprint.

Cite this